GKOS
$184.53
$-4.92 (-2.60%)-2.60%
ClosedLoading chart...
IndexN/A
Market Cap10.88B
Enterprise Value6.51B
Income$-0.02B
Sales$0.11B
EmployeesN/A
P/E-214.57
P/S12.73
P/B9.84
P/C-119.57
EV/EBITDA-44.54
EV/SalesN/A
EPS (ttm)-0.86
EarningsN/A
Gross Margin77.49%
Oper. Margin-17.09%
Profit Margin-36.99%
Volume0.65M
Shs Outstand0.06B
Change-2.60%
Dividend Est.N/A
Dividend Ex-DateN/A
Perf YTDN/A
Perf YearN/A
Perf 3YN/A
Perf 5YN/A
Perf 10YN/A
IPON/A
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $383.48M | $314.71M | $282.86M | $294.01M | $224.96M | $236.98M | $181.28M | $159.25M |
| Cost of Revenue | $94.03M | $75.58M | $68.98M | $66.63M | $91.72M | $38.59M | $25.07M | $21.05M |
| Gross Profit | $289.45M | $239.14M | $213.88M | $227.38M | $133.24M | $198.40M | $156.20M | $138.20M |
| Gross Margin | 75.48% | 75.99% | 75.61% | 77.34% | 59.23% | 83.72% | 86.17% | 86.78% |
| Operating Expenses | $411.82M | $367.84M | $296.20M | $260.26M | $256.79M | $248.69M | $169.21M | $140.49M |
| Operating Income | $-122.37M | $-128.70M | $-82.31M | $-32.87M | $-123.55M | $-50.29M | $-13.00M | $-2.28M |
| Operating Margin | -31.91% | -40.89% | -29.10% | -11.18% | -54.92% | -21.22% | -7.17% | -1.43% |
| Net Income | $-146.37M | $-134.66M | $-99.19M | $-49.59M | $-120.35M | $15.42M | $-12.95M | $-92.00K |
| Net Margin | -38.17% | -42.79% | -35.07% | -16.87% | -53.50% | 6.51% | -7.14% | -0.06% |
| EPS (Basic) | $-2.77 | $-2.78 | $-2.09 | $-1.07 | $-2.70 | $0.41 | $-0.37 | $-0.00 |
| EBITDA | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Stock Option Compensation Expense | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Earnings Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price To Sales Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Shares Outstanding | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Market Capitalization | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Short Term Receivables | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Inventories | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Property, Plant & Equipment | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Investments and Advances | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long-Term Note Receivable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Intangible Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Assets | $974.76M | $940.41M | $1.07B | $1.13B | $1.01B | $818.40M | $206.97M | $165.84M |
| Short Term Debt Incl. Current Port. of LT Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Accounts Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Tax Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Current Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Provision for Risks Charges | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Deferred Tax Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Liabilities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Liabilities | $207.82M | $478.65M | $544.16M | $541.68M | $338.05M | $145.13M | $33.11M | $27.63M |
| Non-Equity Reserves | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Stock - Carrying Value | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Common Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Shareholders Equity | $766.93M | $461.77M | $530.00M | $587.15M | $667.45M | $673.27M | $173.86M | $138.20M |
| Accumulated Minority Interest | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Total Equity | $766.93M | $461.77M | $530.00M | $587.15M | $667.45M | $673.27M | $173.86M | $138.20M |
| Total Liabilities & Stockholders Equity | $974.76M | $940.41M | $1.07B | $1.13B | $1.01B | $818.40M | $206.97M | $165.84M |
| Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Tangible Book Value Per Share | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Full-Time Employees | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Book Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Assets | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Equity | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Return on Invested Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Quick Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Current Ratio | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Metric | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|
| Net Income | $-146.37M | $-134.66M | $-99.19M | $-49.59M | $-120.35M | $15.42M | $-12.95M | $-92.00K |
| Depreciation | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Funds (Non Cash) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Funds from Operations | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Extraordinary Item | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Changes in Working Capital | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Income Taxes Payable | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Operating Activities | $-61.32M | $-57.76M | $-33.08M | $24.71M | $-22.99M | $-369.00K | $18.86M | $25.51M |
| Capital Expenditures | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Assets From Acquisitions | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Fixed Assets and Businesses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase or Sale of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Purchase of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale Or Maturity of Investments | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Sources | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Investing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash Dividends Paid | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Capital Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Repurchase of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Sale of Common Pref Stock | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Proceeds from Stock Options | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance or Reduction of Debt, Net | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Change in Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Issuance of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Reduction of Long Term Debt | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Financing Active Other Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Other Financing Activities Uses | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Cash from Financing Activities | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Exchange Rate Effect | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Change in Cash | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Preferred Dividends (Cash Flow) | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
| Price to Free Cash Flow | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Company coverage
Latest news
Glaukos CFO Alex Thurman Sells $1.6 Million in Stock. What Should Investors Do Now?The Motley Fool Abbott Labs vs. Glaukos: Which Healthcare Stock Is a Better Buy in 2026?The Motley Fool Presbyopia Market to Witness Accelerated Growth at a CAGR of 4.9% During the Forecast Period (2026–2036) Supported by Expanding Treatment Landscape | DelveInsightGlobeNewswire Inc. Nicox prévoit de rembourser intégralement ses dettes financières, NCX 470 ayant été dé-risqué et licencié dans le monde entierGlobeNewswire Inc. Nicox Expects to Fully Repay Financial Debts with NCX 470 De-Risked and Globally LicensedGlobeNewswire Inc. Glaukos Stocks Rides on Strong Product Demand Amid CompetitionBenzinga Will WATCHMAN Sales Aid Boston Scientific's (BSX) Q2 Earnings? - Zacks Investment ResearchZacks Investment Research Truist lifts Glaukos shares target, highlights strong market position - Investing.comInvesting.com
Show 12 more stories
This Visa Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday - BenzingaBenzinga Global Ophthalmic Devices Market Analysis Report 2024-2032 Featuring Johnson & Johnson, Topcon, Canon, Alcon ... - GlobeNewswireGlobeNewswire Inc. Glaukos (GKOS) Reaches 52-Week High: What's Driving the Stock?Zacks Investment Research Glaukos (GKOS) Stock Jumps 3.7%: Will It Continue to Soar?Zacks Investment Research Why Is Waters (WAT) Down 5.1% Since Last Earnings Report?Zacks Investment Research Glaukos (GKOS) Gains 40.4% YTD: What's Driving the Rally?Zacks Investment Research Here's Why You Should Retain Glaukos (GKOS) Stock for NowZacks Investment Research Glaukos (GKOS) Reaches 52-Week High: What's Aiding the Stock?Zacks Investment Research Eye Disease-Focused Glaukos' 'Investor Interest Should Continue To Gain Momentum:' AnalystBenzinga Glaukos (GKOS) Q1 Earnings Miss Estimates, Revenues Up Y/YZacks Investment Research Glaukos (GKOS) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research Can the 4 Medical Device Stocks Hit Targets This Earnings Season?Zacks Investment Research
Insider Trading
View AllInsider
Type
Shares
Price
Value
Date
Company
About the company
Glaukos Corporation operates as an ophthalmic medical technology and pharmaceutical enterprise, primarily focused on pioneering novel therapies for glaucoma, corneal disorders, and retinal diseases. The company offers a range of micro-bypass stents, including iStent, iStent inject, and iStent inject W. These devices are designed to enhance aqueous humor outflow, being inserted during cataract surgery to treat mild-to-moderate open-angle glaucoma. Its promising product pipeline features iStent Infinite, a three-stent system intended for standalone use in patients with refractory glaucoma, as well as iDose TR, a targeted injectable implant that utilizes Glaukos's micro-scale device platform to deliver therapeutic levels of medication. The company distributes its products through a direct sales organization and a network of distributors, serving markets across the United States and internationally. Glaukos Corporation, founded in 1998, is headquartered in San Clemente, California.
Discover more
You may be interested in